Physician profile
Shant Parseghian
NPI 1366476731
$97,893.31
in general payments reported to CMS, 2019-2025
18 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $27K · 2021: $24K · 2022: $28K · 2023: $4,071 · 2024: $241 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,684 · Food and Beverage: $1,206 · Travel and Lodging: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,684.25 |
| Food and Beverage | $1,205.52 |
| Travel and Lodging | $322.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48,575.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $26,280.89 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $21,520.08 | 2019-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $564.87 | 2025 | Omnipod |
| Medtronic, INC. | $164.86 | 2021-2025 | Minimed 780g |
| Beta Bionics, INC. | $156.86 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic Minimed, INC. | $108.25 | 2019-2020 | |
| Dexcom, INC. | $106.78 | 2019-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $91.33 | 2019-2025 | Evenity, Prolia |
| Tandem Diabetes Care, INC. | $72.96 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $62.07 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $59.87 | 2019 | |
| Horizon Therapeutics Plc | $28.17 | 2023 | Tepezza |
| Madrigal Pharmaceuticals | $27.45 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $21.30 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $19.14 | 2024 | Inspire |
| Senseonics, Incorporated | $17.00 | 2019 | |
| Antares Pharma, INC. | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shant Parseghian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.